Xenon Pharmaceuticals (XENE) Long-Term Deferred Tax (2018 - 2026)

Xenon Pharmaceuticals (XENE) has 9 years of Long-Term Deferred Tax data on file, last reported at $12.4 million in Q1 2026.

• Long-Term Deferred Tax for Q1 2026 came in at $12.4 million, up 14.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $12.4 million (up 14.14% YoY), and the FY2025 annual result was $12.9 million, up 33.09% from the prior year.
• Long-Term Deferred Tax eased to $12.4 million in Q1 2026 per XENE's latest filing, from $12.9 million in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $12.9 million in Q4 2025 and troughed at $207000.0 in Q1 2022.
• A 5-year average of $4.4 million and a median of $733000.0 in 2024 frame the typical range for Long-Term Deferred Tax.
• The sharpest annual moves came in 2022 and 2025: Long-Term Deferred Tax slumped 59.73% in 2022, then surged 2619.75% in 2025.
• A 5-year view of Long-Term Deferred Tax shows it stood at $509000.0 in 2022, then soared by 57.56% to $802000.0 in 2023, then surged by 1105.24% to $9.7 million in 2024, then soared by 33.09% to $12.9 million in 2025, then fell by 3.47% to $12.4 million in 2026.
• Business Quant data shows XENE's Long-Term Deferred Tax at $12.4 million in Q1 2026, $12.9 million in Q4 2025, and $11.8 million in Q3 2025.